Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05047172 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

Study acronym: CAPTIVA
StatusActive, Not Recruiting
PhasePhase 3
Started2022-08-02
View on ClinicalTrials.gov ↗

Amendment history

The 50 most recent of 163 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

2026-09-14
23 amendments v140-v162
23 re-verifications since 2026-05-18, no change to tracked fields
2026-05-12
Study Status, Contacts/Locations v139
Trial sites reduced: 117 → 114 locations
2026-05-07
Study Status v138
Primary completion pushed: 2027-01 → 2027-01-31
Completion pushed: 2027-01 → 2027-01-31
2026-04-28
Study Status v137
Re-verified, no change to tracked fields
2026-04-13
Study Status v136
Primary completion moved earlier: 2028-05-31 → 2027-01
Completion moved earlier: 2028-05-31 → 2027-01
Show 23 earlier versions
2026-04-07
Study Status v135
Re-verified, no change to tracked fields
2026-03-09
Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v134
Trial statusRecruiting→Active, Not Recruiting
Study sites130→117
2026-03-05
Study Status v133
Re-verified, no change to tracked fields
2026-03-05
Study Status, Contacts/Locations v132
Study sitesdetails revised at 9 of 130 sites
2026-03-03
Active, Not Recruiting→Recruiting Study Status, Contacts/Locations v131
Trial statusActive, Not Recruiting→Recruiting
Study sites117→130
2026-02-26
6 amendments v125-v130
6 re-verifications since 2026-01-23, no change to tracked fields
2026-01-20
Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v124
Trial statusRecruiting→Active, Not Recruiting
Study sites130→117
2026-01-16
Study Status, Contacts/Locations v123
Study sitescontacts updated at 1 of 130 sites
2026-01-14
Study Status, Contacts/Locations v122
Study sitescontacts updated at 1 of 130 sites
2026-01-09
Study Status, Contacts/Locations v121
Study sitescontacts updated at 2 of 130 sites
2026-01-05
Study Status, Contacts/Locations v120
Study sitesdetails revised at 1 of 130 sites
2025-12-18
Study Status, Contacts/Locations v119
Study sitescontacts updated at 1 of 130 sites
2025-12-12
Study Status, Contacts/Locations v118
Study sitesdetails revised at 3 of 130 sites
2025-12-04
Study Status, Contacts/Locations v117
Study sitescontacts updated at 1 of 130 sites
2025-11-21
Study Status, Contacts/Locations v116
Study sitescontacts updated at 1 of 130 sites
2025-11-18
Study Status, Contacts/Locations v115
Study sitescontacts updated at 1 of 130 sites
2025-11-12
Study Status, Contacts/Locations v114
Study sitescontacts updated at 1 of 130 sites
2025-11-05
Study Status, Contacts/Locations v113
Study sitesdetails revised at 4 of 130 sites
University of Florida
325 trials monitored
See 23 trials at risk
Stroke
3,268 trials monitored
See 122 trials at risk
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
Trial Details
NCT Number NCT05047172
Lead Sponsor University of Florida
Collaborators: National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, Medical University of South Carolina, Janssen Scientific Affairs, LLC, AstraZeneca
Conditions Intracranial Arteriosclerosis, Stroke
Enrollment 1,683 participants
Start Date 2022-08-02
Primary Completion 2027-01-31 (estimated)
Study Completion 2027-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-25